NLRP3 and Hepatic fibrosis: We found that genetic deletion of Nlrp3 or Casp1, or pharmacologic inhibition of Nlrp3 using an oral inhibitor (MCC950) did not ameliorate the development of any of the histological features of fibrosing steatohepatitis (hepatic fibrosis, inflammation, or steatosis) in HFHC-fed mice.